18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma
A Prospective Exploratory Study Evaluating the Diagnostic Usefulness of 18F-mFBG PET Imaging in Pheochromocytoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Peipei Wang, MD
- Phone Number: 86 18511395988
- Email: wpp199411@163.com
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- Recruiting
- The First Affiliated Hospital of Zhejiang University school of medicine
-
Contact:
- Xinhui Su, MD
- Phone Number: 86 13806071262
- Email: suxinhui@zju.edu.cn
-
Hangzhou, Zhejiang, China, 310006
- Recruiting
- The First Affiliated Hospital Zhejiang University School of Medicine
-
Contact:
- Peipei Wang, MD
- Phone Number: 86 18511395988
- Email: wpp199411@163.com
-
Contact:
- Xinhui Su, MD
- Phone Number: 86 13806071262
- Email: suxinhui@zju.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Aged 30-80 years old, primary school or above, with a regular caregiver;
- Clinically diagnosed patients with pheochromocytoma;
- Can provide informed consent, can understand and comply with the study requirements.
Exclusion Criteria:
- Patients with serious primary diseases such as heart, brain, liver, kidney and hematopoietic system;
- Uncontrolled hypertension or high-risk BP (i.e., systolic BP > 180 mmHg or diastolic BP > 110 mmHg);
- Patients with mental disorders or primary affective disorders;
- Unable to understand and adhere to the study protocol or provide informed consent;
- Contraindications to PET imaging (including pregnant women, lactating women, and women of childbearing age with recent childbearing plans, etc.);
- Allergy to imaging agents;
- Patients who were unable to cooperate with PET scanning, such as hypoglycemia, severe pain or tremor.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
18F-MFBG PET/CT in Pheochromocytoma
Each patient receive a single intravenous injection of 18F-MFBG 5.55 MBq/kg and undergo PET/CT or PET/MR scan after 60 min post-injection.
|
Patients with pheochromocytoma malignancies receive 5.55 MBq/kg of 18F-MFBG intravenously followed by PET/CT or PET/MR after 60min of injection.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation between positive and negative 18F-mFBG PET/CT or PET/MR Imaging and pathological diagnosis and treatment effect in patients with pheochromocytoma.
Time Frame: through study completion, an average of 1 year
|
Main outcome measure
|
through study completion, an average of 1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
False positive and false negative results of 18F-mFBG PET/CT or PET/MR Imaging in patients with pheochromocytoma.
Time Frame: through study completion, an average of 1 year
|
Secondary outcome measure
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FAHZU-MFBG-PHEO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.